Chemical engineering

MPR Announces Leadership Transition

Retrieved on: 
Tuesday, January 2, 2024

MPR Associates Inc. is pleased to announce that Tom Lubnow and Jason Gwaltney have been named Principal Officers, succeeding Bob Carritte who will take on another senior strategic leadership role.

Key Points: 
  • MPR Associates Inc. is pleased to announce that Tom Lubnow and Jason Gwaltney have been named Principal Officers, succeeding Bob Carritte who will take on another senior strategic leadership role.
  • "I welcomed Tom to MPR as my office mate many years ago when he joined MPR,” Mr. Coward said.
  • Bob, Tom, and I are excited about the continuing opportunity to work with Bob to help a new generation of MPR engineers and consultants become industry leaders.”
    As part of the executive leadership transition, Mr. Coward will also shift to a similar role as Mr. Carritte in January 2025.
  • His focus in 2024 will include working with Mr. Lubnow, Mr. Gwaltney, Mr. Carritte, and other MPR leaders to support a smooth transition and position MPR to continue the high levels of success and accomplishment the firm has consistently achieved for its 60-year history.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Retrieved on: 
Friday, December 22, 2023

At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.

Key Points: 
  • At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommendations of the board of directors.
  • The Company’s shareholders also approved the appointments of Mr. Marc Dunoyer and Dr. Tyrell Rivers as directors of the Cellectis board of directors, which appointment remains subject to the completion of the Additional Investment.
  • “We are grateful to our shareholders for supporting the Additional Investment and we are looking forward to welcoming Mr. Dunoyer and Dr. Rivers to our board of directors.
  • The detailed results of the vote and the resolutions are available on Cellectis’ website:

Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth

Retrieved on: 
Friday, December 22, 2023

TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.

Key Points: 
  • TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to 100%.
  • Additionally, Dr. Steve Hsu, Chairman of Genovior Biotech Corporation, has been appointed as the CEO of Polaris Group.
  • These two highly prospective product lines will serve as the dual engines propelling Polaris Group's future growth.
  • Consequently, Genovior Biotech fills critical gaps for Polaris Group, providing not just high-quality manufacturing capabilities but also a substantial entry into the market for peptide products.

Pacira Appoints Frank D. Lee as Chief Executive Officer

Retrieved on: 
Thursday, December 21, 2023

TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his roles as Chief Executive Officer and Chairman of the Board, effective January 1, 2024, and will remain with the company through August 2025 in an advisory capacity to help ensure a smooth transition. In connection with Mr. Stack’s retirement, the Board has elected Paul Hastings, Lead Independent Director, as Chair of the Board, also effective January 2, 2024.

Key Points: 
  • TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the “Board”) has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024.
  • Most recently he served as Chief Executive Officer and member of the board of directors of Forma Therapeutics from March 2019 through its acquisition by Novo Nordisk in October 2022.
  • Prior to joining Genentech, Mr. Lee spent approximately 13 years across Novartis, Janssen and Eli Lilly in engineering, manufacturing, sales/marketing and business development.
  • On December 20, 2023, in connection with Mr. Lee’s appointment as Chief Executive Officer, the Board approved the grant of inducement awards to Mr. Lee.

RetinalGeniX Technologies Inc. Appoints Anatoly Dritschilo, M.D. to the Company’s Medical Advisory Board

Retrieved on: 
Thursday, December 21, 2023

PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.

Key Points: 
  • PETALUMA, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX Technologies Inc. (OTCQB: RTGN) (“RetinalGeniX” or the “Company”), today announced that Anatoly Dritschilo, M.D.
  • has joined the Company’s Medical Advisory Board.
  • RetinalGeniX is an ophthalmic research and development med-device and therapeutic drug development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies.
  • Dr. Dritschilo is the CEO and Chairman of the Board of Directors of Shuttle Pharmaceuticals Holdings, Inc.

Reliq Health Technologies, Inc. Announces the Appointment of Directors

Retrieved on: 
Friday, December 15, 2023

First elected as a City Councillor in Barrie, in 2006, Alex continued to serve at the Municipal level of government until 2014.

Key Points: 
  • First elected as a City Councillor in Barrie, in 2006, Alex continued to serve at the Municipal level of government until 2014.
  • “We are pleased to welcome Alex and Chris as new directors,” said Brian Storseth, director of the Company.
  • Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.
  • Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

Reliq Health Technologies, Inc. Announces Management Changes

Retrieved on: 
Monday, December 11, 2023

Dr. Crossley will continue to work with the Company as an advisor to ensure that there is no disruption to operations.

Key Points: 
  • Dr. Crossley will continue to work with the Company as an advisor to ensure that there is no disruption to operations.
  • The Company would like to thank Dr. Crossley for her eight years of dedicated service as CEO of Reliq and wishes her the best with her recent health issues, and hopes she has a speedy recovery.
  • Reliq Health Technologies is a rapidly growing global healthcare technology company that specializes in developing innovative Virtual Care solutions for the multi-billion dollar Healthcare market.
  • Reliq Health Technologies trades on the TSX Venture under the symbol RHT, on the OTC as RQHTF and on the Frankfurt Stock Exchange under the WKN: A2AJTB.

American Institute of Chemical Engineers Honors Organizations and Leaders for Empowering Possibilities

Retrieved on: 
Monday, December 11, 2023

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The American Institute of Chemical Engineers (AIChE) celebrated the contributions of the companies and the leaders of AdvanSix Inc. and Air Products, and showcased the good works of chemical engineers and their employers, at the 2023 AIChE Gala, held December 7 in New York City.

Key Points: 
  • NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The American Institute of Chemical Engineers (AIChE) celebrated the contributions of the companies and the leaders of AdvanSix Inc. and Air Products, and showcased the good works of chemical engineers and their employers, at the 2023 AIChE Gala, held December 7 in New York City.
  • The award for AdvanSix was accepted by Erin Kane, the company’s President and Chief Executive Officer.
  • In accepting the award at the gala, Kane shared “AdvanSix is grounded in our focus on good chemistry.
  • Mitragotri thanked the AIChE foundation for recognizing drug delivery as a prominent contribution of chemical engineers to the field of medicine.

CarbonCapture Inc. Promotes Dr. Saeb Besarati to Chief Technology Officer

Retrieved on: 
Monday, December 4, 2023

LOS ANGELES, Dec. 04, 2023 (GLOBE NEWSWIRE) -- CarbonCapture Inc. (CarbonCapture), a leading direct air capture (DAC) company, today announced the promotion of Dr. Saeb Besarati to the position of Chief Technology Officer (CTO).

Key Points: 
  • LOS ANGELES, Dec. 04, 2023 (GLOBE NEWSWIRE) -- CarbonCapture Inc. (CarbonCapture), a leading direct air capture (DAC) company, today announced the promotion of Dr. Saeb Besarati to the position of Chief Technology Officer (CTO).
  • Saeb's journey with CarbonCapture began in 2019, when he joined the company’s founding team as Director of Systems Engineering.
  • Saeb holds a PhD degree in Chemical Engineering and a Master’s degree in Mechanical Engineering with specialization in Thermal Science.
  • I am excited about his transition into the formal role of Chief Technology Officer and enthusiastic about our continued collaboration," stated Adrian Corless, CEO of CarbonCapture Inc.

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

Retrieved on: 
Monday, December 4, 2023

Dr. McCue joins TScan with over 20 years of experience in biologics and cell therapy manufacturing, including process/analytical development, technical operations, clinical development, and commercialization of T cell therapy products.

Key Points: 
  • Dr. McCue joins TScan with over 20 years of experience in biologics and cell therapy manufacturing, including process/analytical development, technical operations, clinical development, and commercialization of T cell therapy products.
  • “We are delighted to welcome Justin to TScan.
  • Prior to joining Avectas, Dr. McCue was Vice President of Technical Operations at Repertoire Immune Medicines where he led CMC development and clinical manufacturing of their multi-targeted antigen-specific T-cell platform.
  • Dr. McCue holds a bachelor’s degree in chemical engineering from the University of California, Berkeley, and a Ph.D. in Chemical Engineering from the Massachusetts Institute of Technology.